Stocks / NASDAQ / Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

Industry: Health Care – Major Pharmaceuticals

Stock Symbol: KPTI – NASDAQ

Animal Usage: Animal Testing

Our Opinion

Karyopharm Therapeutics Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.

Supporting Evidence:

The company stated in the following press release that they conduct pre-clinical trials of their drugs on animals.

“Preclinical data, generated mainly by Karyopharm’s academic collaborators, has shown the efficacy of orally-administered KPT-350 in animal models of ALS, MS and TBI.” Read the following article

Company Description

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, which discovers, develops, and commercializes drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA. [Source: MarketWatch]

Company Website: https://www.karyopharm.com

Contact: https://www.karyopharm.com/contact; IR: info@karyopharm.com;